Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...

Annual whole-body, low-dose computed tomography (WBLDCT) can improve the management of smoldering multiple myeloma (SMM), ...

Researchers have demonstrated the potential of the innovative optical genome mapping (OGM) technique for the diagnosis, ...

Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment ...

Gut microbiome analysis of patients with multiple myeloma receiving idecabtagene vicleucel (ide-cel) therapy revealed specific bacterial species linked to treatment response and toxicity outcomes.

Follow along on our guide to Multiple Myeloma, a cancer of the bone marrow's infection-fighting plasma cells. As cancerous plasma cells build up in bone marrow, they crowd out healthy blood cells ...

Therapy-related B-lymphoblastic leukemia (B-ALL) following treatment for multiple myeloma is a rare occurrence. Despite its rarity and the lack of recognition by the World Health Organization as a ...

When you have treatment for multiple myeloma, the hope is the medicines will kill your cancer cells and keep your healthy cells. The more the drugs accomplish that, the better you’ll feel.

Multiple myeloma (MM), which is caused by the transformation and uncontrolled proliferation of blood cells that normally produce antibodies 1, is the second most common haematological cancer ...